our patients were examined at the manufacturer's laboratory and were found to be in perfect condition. Placebo patches containing all the components of the patches apart from hyoscine were applied in all of the men; no local skin reactions were observed.
Comment
This study showed an unexpectedly high rate (10%) of allergic contact dermatitis to transdermal hyoscine in healthy men treated for several months. Allergic contact dermatitis (type IV delayed hypersensitivity) was diagnosed by well established clinical criteria and was further confirmed by the absence ofany reaction to a placebo patch.
Our results contrast with those of studies conducted by the manufacturer (Alza Corporation, California, United States), in which no delayed contact sensitisation occurred. In those studies 203 subjects were examined according to a protocol that included the consecutive application of nine hyoscine patches and the application of a tenth patch after two weeks' rest. The design of these studies, however, does not rule out the possibility of delayed type IV hypersensitivity occurring as a result of more prolonged use of transdermal hyoscine. Studies of the long term use of transdermal clonidine showed an incidence of allergic contact dermatitis of 10-38% after three to 12 months of continuous treatment.3 On the other hand, delayed hypersensitivity to transdermal glyceryltrinitrate, which is commonly used in long term and repeated regimens, is rare.
We conclude that delayed hypersensitivity may be a serious disadvantage of giving drugs transdermally. Evaluation of new transdermal treatments should exclude the possibility of delayed hypersensitivity, which in our experience may develop even after several months of repeated application. and vasodilator properties, counterregulating the renin-angiotensin-aldosterone system.' We investigated whether it is present in the fetal circulation by using cordocentesis to obtain fetal blood samples, in some cases before and after transfusions for rhesus isoimmunisation.
Methods and results
Blood samples (0 5 ml) were collected on 15 occasions from nine fetuses (from the umbilical vein in 14 and the heart in one) undergoing treatment for rhesus isoimmunisation. The mean gestational age was 28 weeks (range 20-32) and the mean packed cell volume 0-29 (range 0 22-0 39). Samples were obtained before and after transfusion from eight fetuses and after transfusion alone in one case. A sample of donor blood was collected at each transfusion.
Blood samples were also obtained from 12 fetuses (from the umbilical vein in 10 and the heart in two) undergoing cordocentesis to determine the karyotype. In seven cases this was because of a structural anomaly (gastroschisis (one), urinary tract obstruction (three), duodenal atresia (one), and diaphragmatic hernia (two)). In 10 cases the karyotype was normal, but one fetus had triploidy and another trisomy 21. The mean gestational age of this group was 23 weeks (range 17-34).
In each case samples of maternal blood were collected before the procedure. Umbilical cord and maternal venous blood samples were also obtained in eight normal term deliveries.
Atrial natriuretic peptide was measured by pre-extracted radioimmuoassay,2 the results being expressed in pmol/l (10 pg/ml=3 2 pmol/l). The figure shows the results for the paired maternal and fetal umbilical samples in each group, the one unpaired and three intracardiac samples being excluded. Statistical analysis was by Wilcoxon rank sum test or coefficient of correlation as indicated.
Before transfusion the fetal atrial natriuretic peptide concentrations in the isoimmunised group were significantly higher (mean 49 (range 12-86) pmol/l) than in those in the karyotype group (34 (8-57) pmol/l; p<005) and in the group delivered at term (16 (7-29) pmol/l; <0-01). Fetal concentrations in the karyotype group were also significantly higher than those in the group delivered at term (p<005). Taken together, the fetal concentrations in the isoimmunised and karyotype groups showed no significant correlations with fetal packed cell volume, fetal albumin concentration, gestational age, or maternal atrial natriuretic peptide concentration. In both the isoimmunised group and the karyotype group fetal concentrations of atrial natriuretic peptide were significantly higher than corresponding maternal values (p<001). The concentrations in the three intracardiac samples were 73, 100, and 124 pmol/l.
After 
Comment
These preliminary results show that atrial natriuretic peptide circulates in the fetus and placenta. The higher fetal than maternal concentrations and the values in the three intracardiac samples are consistent with production by the fetus.
The higher fetal concentrations in the isoimmunised group may reflect expansion of the fetoplacental plasma volume, which suggests that release of the peptide in fetuses is regulated in the same way as that in adults. The dynamic response to intravascular transfusion in this series (despite the dilutional effect of the donor blood) is supported by experimental work3 and BrMedJ 1989; 298:1222-3 Morphine and dryness of the mouth I D White, P J Hoskin, G W Hanks, J M Bliss Morphine sulphate taken by mouth is the drug of choice when a strong opioid analgesic is required to control pain caused by cancer.' Specific gastrointestinal side effects such as nausea, vomiting, reduced gastrointestinal motility, and reduced biliary and pancreatic secretions are well documented.2 Dryness of the mouth is not generally recognised as a side effect of morphine,2 but clinical experience suggests that it is a common complaint of patients with cancer who are receiving it. We studied the prevalence of dryness of the mouth in patients with cancer to see whether it is associated with the use of morphine.
Patients, methods, and results
All patients admitted to this hospital during a period of eight weeks were entered into the study except those who had other reasons for having a dry mouthnamely, those receiving radiotherapy or surgery to the head and neck, those who had received a general anaesthetic within the previous 48 hours, those whose intake by mouth was restricted, and those receiving cytotoxic chemotherapy.
We recorded demographic data; details of the current analgesic being taken (drug, dose, preparation, and duration of treatment at the current dose) and of other drug treatment; whether dentures were worn; and whether there was evidence of oral candidiasis. Patients completed a questionnaire comprising two four point categorical scales (Do you suffer from a dry mouth? How dry has it been in the past 24 hours?) and a 10 cm visual analogue scale, which also measured the severity of the dryness during the preceding 24 hours and was included to support the results from the second categorical scale.
A high degree of concordance was found between the categorical and visual analogue scales (Goodman and Kruskal's gamma statistic=0-97 The table shows the results. A highly significant association was found between the use ofmorphine and dryness of the mouth (test for trend (stratified) x2= 20-62, df= 1, p<00005). When concurrent treatment was allowed for patients receiving morphine were roughly four times more likely to have a dry mouth of any severity than patients taking weak opioid, non-opioid, or no analgesics (95% confidence interval for odds ratio 2-0 to 7-2 by logistic regression analysis4).
Comment
Our results show a clear association between the use of morphine and dryness of the mouth in this sample of patients. The mechanism for this effect is unclear. We
